COVID-19 is a fast-moving pandemic. The infection has a mortality rate of 3-6%. Patients with underlying CVD are at higher risk of contracting COVID-19 and have a worse prognosis.
Our experts from Wuhan China and SIngapore have shared clinical experiences from frontline China on management of COVID-19 patients with underlying heart disease. Topics include:

  • Diagnosis to management of COVID-19 patients with underlying CVD: Learnings from China
  • COVID-19 and Anti-hypertensive Drugs
  • Clinical Case sharing - experience from Singapore

Faculty-Icon

Faculty

Speaker

Dr. Zhou Ning, Wuhan China

Deputy Chief Physician, Associate Professor, Postgraduate Supervisor Department of Cardiovascular Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Read More

Moderator

Dr. Jack Tan, Singapore

Deputy Head of Cardiology and Director of the Coronary Care Unit, National Heart Centre Singapore
Head of Cardiology, Sengkang Hospital President, Asian Pacific Society of Cardiology
Read More

Speaker

Dr Ling Li Min, Singapore

Infectious Diseases Physician National Centre for Infectious Diseases(NCID) and Tan Tock Seng Hospital(TTSH), Singapore
Read More

Panelist

Prof Koji Hasegawa, Japan

Director of the Division of Translational Research, National Hospital Organization Kyoto Medical center
Read More

Panelist

Dr LAM ho, Hong Kong

Consultant, Department of Medicine and Geriatrics, Cath Lab Director, Tuen Mun Hospital, Hong Kong. Council Member, Hong Kong Medical Association
Read More
Faculty-Icon

Webinar Recordings

Faculty-Icon

Q&As of the webinar will be available soon

Faculty-Icon

Related Webinar Recordings

Subscribe to stay updated on future webinars

Supported By: